

Exhibit 1: Key financials

Company	Revenue (INR mn)					EBITDA (INR mn)					PAT (INR mn)				
	Q1FY26	Q4FY25	Q1FY25	QoQ (%)	YoY (%)	Q1FY26	Q4FY25	Q1FY25	QoQ (%)	YoY (%)	Q1FY26	Q4FY25	Q1FY25	QoQ (%)	YoY (%)
Sun Pharma	1,38,514	1,29,588	1,26,528	6.9	9.5	40,726	34,249	36,076	18.9	12.9	29,961	28,891	28,356	3.7	5.7
Dr Reddy's	85,452	85,060	76,727	0.5	11.4	21,497	20,497	21,266	4.9	1.1	14,178	16,547	13,924	(14.3)	1.8
Aurobindo	78,681	83,821	75,670	(6.1)	4.0	16,034	17,919	16,196	(10.5)	(1.0)	8,250	9,035	9,185	(8.7)	(10.2)
Zydus Lifesciences	65,737	65,279	62,075	0.7	5.9	20,243	21,649	21,092	(6.5)	(4.0)	14,140	13,905	14,393	1.7	(1.8)
Cipla	69,575	67,297	66,939	3.4	3.9	17,781	15,376	17,158	15.6	3.6	12,976	12,218	11,776	6.2	10.2
Lupin	62,683	56,671	56,003	10.6	11.9	16,414	12,921	13,614	27.0	20.6	11,589	8,317	8,856	39.4	30.9
Biocon	39,419	44,170	34,329	(10.8)	14.8	7,489	10,782	6,204	(30.5)	20.7	314	3,252	422	(90.3)	(25.5)
Glenmark	32,644	32,562	32,442	0.3	0.6	5,805	5,610	6,102	3.5	(4.9)	3,129	3,328	3,554	(6.0)	(12.0)
Torrent Pharma	31,780	29,590	28,590	7.4	11.2	10,470	9,640	9,240	8.6	13.3	5,591	5,160	4,709	8.4	18.7
JB Chemicals	10,939	9,495	10,044	15.2	8.9	3,159	2,264	2,804	39.5	12.7	2,136	1,457	1,768	46.6	20.8
Ajanta Pharma	13,027	11,704	11,449	11.3	13.8	3,765	2,972	3,304	26.7	14.0	2,747	2,253	2,458	22.0	11.8
Alkem	33,711	31,438	30,318	7.2	11.2	7,391	3,913	6,086	88.9	21.4	6,531	3,059	5,452	113.5	19.8
Alembic Pharma	17,107	17,696	15,617	(3.3)	9.5	2,814	2,719	2,368	3.5	18.8	1,529	1,564	1,345	(2.2)	13.6
Natco	13,289	12,210	13,626	8.8	(2.5)	5,710	5,731	8,048	(0.4)	(29.1)	4,923	4,810	6,685	2.3	(26.4)
Divi's	24,100	25,850	21,180	(6.8)	13.8	7,290	8,860	6,230	(17.7)	17.0	5,160	6,543	4,307	(21.1)	19.8
Abbott India	17,384	16,046	15,576	8.3	11.6	3,890	4,285	3,910	(9.2)	(0.5)	3,659	3,670	3,280	(0.3)	11.5
Pfizer	6,031	5,919	5,629	1.9	7.1	2,100	2,275	1,775	(7.7)	18.3	1,918	1,966	1,507	(2.5)	27.2
GSK Pharma	8,052	9,744	8,147	(17.4)	(1.2)	2,512	3,332	2,305	(24.6)	9.0	2,050	2,629	1,823	(22.0)	12.4
Piramal Pharma	19,337	27,541	19,511	(29.8)	(0.9)	1,067	5,610	2,045	(81.0)	(47.8)	(1,031)	1,535	(886)	(167.2)	16.4
Akums	10,240	10,555	10,191	(3.0)	0.5	1,290	939	1,242	37.3	3.9	635	1,313	575	(51.7)	10.4
Innova	3,515	3,147	2,943	11.7	19.5	521	477	422	9.3	23.5	310	296	295	4.9	5.2
Cohance Lifesciences	5,493	8,404	4,881	(34.6)	12.5	1,120	2,292	1,251	(51.1)	(10.5)	570	1,290	754	(55.8)	(24.4)
Gland Pharma	15,056	14,249	14,017	5.7	7.4	3,678	3,475	2,644	5.8	39.1	2,155	1,865	1,438	15.5	49.9
Coverage Universe	8,01,767	7,98,037	7,42,432	0.5	8.0	2,02,765	1,97,788	1,91,382	2.5	5.9	1,33,418	1,34,902	1,25,976	(1.1)	5.9

Source: Company data, I-Sec research

Exhibit 2: Valuation summary

Company	Mkt. Cap (INR bn)	Target Price (INR)	Rating	EPS (INR)			RoCE (%)			P/E (x)			EV/EBITDA (x)		
				FY25	FY26E	FY27E	FY25	FY26E	FY27E	FY25	FY26E	FY27E	FY25	FY26E	FY27E
Sun	4092	1,800	ADD	47.2	50.0	55.7	15.6	15.3	15.4	36.1	34.1	30.6	26.3	23.5	20.8
Dr Reddy's	1040	1,200	HOLD	70.2	62.9	57.5	16.5	12.4	10.3	17.8	19.8	21.7	11.8	11.8	11.9
Aurobindo	615	1,300	BUY	60.3	64.8	82.4	10.2	10.0	11.7	17.4	16.2	12.7	9.3	8.2	6.6
Lupin	900	1,950	HOLD	76.9	87.2	95.5	19.6	18.4	18.2	25.7	22.6	20.7	16.5	14.5	13.2
Cipla	1286	1,800	BUY	62.7	64.5	69.0	18.6	16.2	15.4	25.4	24.7	23.1	16.9	16.3	14.9
Zydus Lifesciences	1013	910	HOLD	44.9	43.1	40.8	18.9	15.4	13.1	22.0	22.9	24.2	14.0	14.0	14.1
Biocon	480	270	SELL	2.3	4.7	9.3	2.1	2.4	3.4	153.2	76.2	38.5	21.2	17.2	13.1
Glenmark	546	1,570	SELL	49.2	55.0	68.7	16.9	14.4	14.2	39.3	35.2	28.2	23.2	20.6	17.0
Torrent	1364	3,530	HOLD	57.5	64.5	75.7	19.0	12.7	10.5	64.1	57.1	48.7	37.2	32.0	24.0
Alkem	649	6,065	BUY	181.1	201.8	166.7	21.0	20.6	15.1	30.0	26.9	32.5	25.3	22.1	19.4
Ajanta	333	2,500	REDUCE	74.0	87.0	100.7	26.0	26.6	24.9	37.2	31.6	27.4	27.0	22.8	19.4
Alembic	191	900	HOLD	29.0	33.0	40.5	10.8	11.1	12.5	33.6	29.5	24.1	20.0	17.4	14.9
JB Chemicals	271	1,800	HOLD	42.4	49.4	57.2	25.8	22.2	19.3	41.3	35.4	30.6	25.9	22.3	19.3
Natco	161	810	REDUCE	104.5	60.1	42.7	26.8	12.5	7.3	8.4	14.7	20.7	6.2	10.3	16.3
Abbott India	678	35,750	ADD	665.6	774.9	889.4	36.3	37.5	38.8	47.9	41.2	35.9	39.1	34.1	29.6
Pfizer India	259	5,900	BUY	139.2	161.9	184.9	16.3	16.6	17.0	41.9	36.0	31.6	32.4	27.6	24.3
GSK Pharma	474	2,600	REDUCE	54.5	59.7	67.8	53.7	50.1	45.8	51.4	46.9	41.3	38.1	35.2	31.0
Divi's	1630	5,400	REDUCE	81.2	95.5	135.1	14.6	15.8	19.9	75.8	64.4	45.5	54.3	45.3	32.7
Piramal Pharma	255	265	BUY	0.7	1.3	4.6	1.4	2.8	5.9	280.2	152.1	42.1	20.7	22.2	14.9
Akums	74	655	BUY	21.0	19.0	24.5	12.0	9.9	10.2	22.9	25.2	19.6	14.9	12.1	10.0
Innova Captab	52	1,000	ADD	22.4	29.0	39.9	10.8	12.2	14.5	40.6	31.4	22.8	29.4	20.9	15.5
Cohance Lifesciences	338	1,250	BUY	14.0	14.2	20.6	15.3	14.7	17.3	63.1	62.2	43.0	43.2	37.3	27.6
Gland	318	2,115	ADD	42.4	58.0	76.1	7.2	9.0	10.5	46.3	33.9	25.8	27.7	23.4	18.8

Source: Company data, I-Sec research

Exhibit 3: Earnings revision for coverage universe post Q1FY26 results

Company	Target Price (INR)	EPS (INR) - Pre-results		EPS (INR) - Post-result		Earnings revision		Rating	
		FY26E	FY27E	FY26E	FY27E	FY26E	FY27E	Pre-result	Post Result
Sun	1,800	52.9	59.0	50.0	55.7	-5.5	-5.5	ADD	ADD
Dr Reddy's	1,200	71.4	57.2	63.7	58.2	-10.8	1.8	HOLD	HOLD
Aurobindo	1,300	69.8	83.2	64.8	82.4	-7.1	-1.0	ADD	BUY
Lupin	1,950	87.1	95.9	87.2	95.5	0.1	-0.5	HOLD	HOLD
Cipla	1,800	63.8	68.1	64.5	69.0	1.1	1.3	BUY	BUY
Zydus Lifesciences	910	43.5	41.2	43.1	40.8	-0.8	-1.0	HOLD	HOLD
Biocon	270	4.1	8.6	4.7	9.3	14.2	8.4	SELL	SELL
Glenmark	1,570	59.6	73.5	55.0	68.7	-7.6	-6.6	SELL	SELL
Torrent	3,530	69.0	74.1	70.5	75.7	2.2	2.1	HOLD	HOLD
Alkem	6,065	193.1	160.4	200.9	166.7	4.0	3.9	ADD	BUY
Ajanta	2,500	87.2	102.5	87.0	100.7	-0.2	-1.8	REDUCE	REDUCE
Alembic	900	34.5	42.2	33.0	40.5	-4.2	-4.0	HOLD	HOLD
JB Chemicals	1,800	49.0	56.9	49.1	57.2	0.3	0.4	ADD	HOLD
Natco	810	68.2	46.7	60.1	42.7	-11.9	-8.7	REDUCE	REDUCE
Abbott India	35,750	773.6	891.4	774.9	889.5	0.2	-0.2	BUY	ADD
Pfizer India	5,900	158.3	181.4	161.9	184.9	2.3	1.9	ADD	BUY
GSK Pharma	2,600	60.2	67.9	59.7	67.8	-0.9	-0.1	REDUCE	REDUCE
Divi's	5,400	106.1	139.9	95.5	135.1	-10.0	-3.4	REDUCE	REDUCE
Piramal Pharma	265	1.3	4.6	1.3	4.6	-4.6	-0.2	BUY	BUY
Akums	655	22.8	30.3	19.0	24.5	-16.5	-19.1	BUY	BUY
Innova	1,000	29.2	41.1	29.0	39.9	-0.8	-2.9	ADD	ADD
Cohance	1,250	16.2	22.4	14.2	20.6	-12.2	-8.2	BUY	BUY
Gland Pharma	2,115	56.4	73.3	58.0	76.1	2.9	3.8	ADD	ADD

Source: Company data, I-Sec research

Exhibit 4: Q1FY26 – takeaways on India business

Company	India Business Commentary
Sun Pharma	<ul style="list-style-type: none"> India business grew 13.9% YoY as compared to IPM (9%), driven by volumes of existing products, new products and price hikes. Prescription business was the major growth driver in the quarter. GLP-1 drugs have so far not had any sales/volume impact on oral solid diabetes drugs like DPP4 and SGLT-2 inhibitors. The company aims to be in the first wave of generic GLP-1 launch in India. It has launched 5 new products in Q1FY26.
Dr. Reddy's	<ul style="list-style-type: none"> India business growth was driven by price hikes, new launches and commercial execution. It launched five new brands in Q1FY26 including two innovative brands Beyfortus (RSV Vaccine) and Sensimmune (Acarizex slit) It has expanded collaboration with Sanofi to launch Beyfortus (nirsevimab), a novel drug for preventing Respiratory Syncytial Virus (RSV) in India.
Cipla	<ul style="list-style-type: none"> Domestic sales grew 5.9% YoY due to slowdown in branded market, while momentum in trade generics and consumer biz was strong. Acute therapies account for ~58-59% of India revenue and grew at 4-5%. Share of respiratory and anti-infective drugs is higher in India revenue. Market growth for these therapies stood at 5% in Q1FY26, which also impacted Cipla's overall growth. Cipla launched a new division for triple dose combination products in India. Three new triple combination products are likely to be launched in the near term. It launched seven new products in Q1FY26. The company is looking to expand its distribution network to boost growth in consumer portfolio.
Lupin	<ul style="list-style-type: none"> Domestic revenue growth was impacted by loss of exclusivity in few in-licensed products diabetes products. In-licensed products now account for ~6% of India sales vs 12% in FY25. GLP-1 products are a core part of its India strategy. It may look to in-license GLP1 products in India. Oncology, CNS and GI are also key therapies of focus. The company has nearly 80 products lined up for launch in next 5 years. The company may also introduce products from its novel pipeline and biosimilars in India market. Diagnostic business in India will likely break-even next year.
Zydus Lifesciences	<ul style="list-style-type: none"> Branded business in India grew at a faster pace of 9% (vs. reported growth of 8% in India) Domestic formulation business growth was driven by strong performance across key therapies. Share of chronic therapies stood at 43.7%, expansion of over 420bps in last 3 years. The company shall launch new formulation of Semaglutide in India, which would have ease in administration. India consumer business was impacted by seasonality excluding which the sales stood in double-digits.
Torrent	<ul style="list-style-type: none"> Addition of MRs and price hikes continue to fuel growth in India (+10.8% YoY). Currently, MR strength at 6,600 which is expected to reach 7000 by end of FY26. 200 MRs were added in Q1, similar addition expected in Q3. The company plans to retain MRs of JB Chemicals post-acquisition. Torrent's chronic business grew at 13% vs. IPM growth of 9% driven by cardiac, diabetes, gastro and CNS therapies. Investment in marketing of Tedibar is yielding result, its growing faster than overall India growth of Torrent Consumer brands account for 10-15% of India sales. It has launched 4-5 new molecules and 9-10 line-extension brands in India. Semaglutide injectable and oral solid dose are expected to have a decent market size post generic entry. Torrent is conducting trials for oral solid product and have partnered for injectable product.
Alkem	<ul style="list-style-type: none"> Alkem's India business growth of 12% YoY in Q1FY26 was its fastest in the last six quarters, led by growth in branded generics. As per IQVIA (SSA) data, the company outperformed market growth across seven therapies, primarily gastrointestinal (~1.6x market growth) and vitamin, minerals and nutrients (~2.3x). 30% of sales of branded biz is under price control. M&A in India will likely be focused towards strengthening chronic biz and funded through cash on books while leveraging the balance sheet may be considered if the assets can add decent value. Acquisitions (Adroit and Bombay ortho) contributed 0.5% to growth of India business. It recorded sales of INR 25mn from medtech business.
Glenmark	<ul style="list-style-type: none"> India business revenue grew mere 3.7% YoY impacted by discontinuation of non-core brands in Q4FY25 and underperformance in diabetes segment. Its India business market share stood at 2.3%, as per IQVIA MAT Jun'25. Lirafit has already gained 50% market share, company plans to launch other GLP1 agonists ahead and further ramp-up is likely to happen from Q2FY26 as supplies normalise. The company expanded innovative oncology portfolio with the launch of Tevimbra and Brukinsa towards the end of Q1FY26. Witnessing continuous improvement in market shares across cardiac, dermatology and respiratory therapies. Consumer care grew 20% YoY with strong growth in flagship brands.

Company	India Business Commentary
JB Chemicals	<ul style="list-style-type: none"> India business grew 14% YoY (volume 7% and price 7%) aided by traction in acute, ophthalmology and chronic portfolio. As per IQVIA, the acquired ophthalmology brands from Novartis had revenue of INR 570mn in Q1FY26. As per IQVIA JB Chem grew 13% vs. 9% industry growth. JB chemicals registered volume growth of 4% vs. 1.5% market volume. Ownership of the in-licensed ophthalmology brands of Novartis shall be transferred to JB Chemicals in FY28, which should help the company improve margins. Sporlac entered top 300 and growing at high teen growth, Rantac and Metrogyl was flat. Acute growth was driven by Sporlac and eye drops portfolio. Razel franchise crossed INR 1bn of sales as per IQVIA In ophthalmology, it has a field force of 105 covering 14k ophthalmologists, growing at 19%. Cilacar is growing at a run rate of 20%+ and the momentum is expected to continue.
Ajanta Pharma	<ul style="list-style-type: none"> Growth of 15.9% YoY was driven by better volumes and new launches. India business growth has outperformed market growth due to strong presence in chronic therapies. It added 70 MRs in Q1, taking the total to 3,520. Addition of newer therapies such as nephrology and gynaecology in India, which should drive growth ahead along with its existing key therapies. Products under NLEM account for 11% of sales. Met-XL (all SKUs) has annual revenues of INR 3bn.
Alembic Pharma	<ul style="list-style-type: none"> India business growth was tepid at 4.7% YoY due to execution challenges in specialty portfolio (up 1% YoY) and slowdown in acute market. It launched three products in Q1FY26. Growth in animal healthcare segment continues to be strong led by robust execution. The company is not looking to expand its field force (5,500 MRs currently) in India.
Natco	<ul style="list-style-type: none"> Domestic formulations revenue grew at a slower pace of 4.7% YoY. Natco intends to among the first few companies to launch semaglutide (GLP-1 product) in India. In India, Natco is prepared for the launch of Risdiplam and is awaiting approval from the Delhi High Court. Base business growth to continue at 7-8% YoY. In agrochemicals segment, the company launched 5 products in Q1FY26, including a couple of unique products such as Glanz along with herbicides and insecticides.
GSK	<ul style="list-style-type: none"> Revenue grew mere 1.2% YoY mainly due to supply constraints at the CMO site and muted performance in a few therapies. Supply constraints due to a fire incident at a CMO site impacted overall growth by 2%. Weaker growth across topical corticosteroids and anti-infectives dragged growth in the general medicine segment (volumes declined by ~1.7% in Q1). GSK's represented market grew 6.6% while general medicine division volumes declined by 2%. Key brands such as Eltroxin and Calpol (supply issue at CMO site) witnessed headwinds; however, recovery is underway. Respiratory portfolio led by Nucala and Trelegy continues to gain market share, while it is recording sales of ~10,000 monthly doses of Shingrix. The company has taken a price hike across its portfolio (40% under NLEM); its benefit should flow through from Q2FY26. Derma portfolio growth is weaker in Q1 every year. Growth is expected to bounce back by end of Q2FY26. It has a MR force of 2,000 on field in India across vaccines, general medicine and specialty divisions. Volumes for the vaccine portfolio grew 8.6%. Paediatric vaccines portfolio growth was led by Boostrix, Varilrix & Havrix. GSK maintains leadership in paediatric vaccine segment with 20.8% market share. Captive manufacturing accounts for 35% of revenue, balance is sourced from CMOs.
Akums	<ul style="list-style-type: none"> Q1FY26 revenue was muted due to slowdown across verticals; however, better product mix aided gross margin expansion (+170bps YoY). CDMO business' growth dampened (+4.0% YoY) due to lower API prices (-2.5% YoY). API prices remain soft and have declined ~10-12% in the last 12 months. Prices of top-200 APIs witnessed a double-digit decline. Branded and generic formulations' revenue declined 1% YoY (flat QoQ) to INR 1.7bn, mainly due to consolidation in trade generic segment. It received 27 approvals from DCGI in Q1FY26, as compared to 35 approvals in FY25. Traction at the injectables and hormonal facility, along with a strong order book and improvement in mix, should aid CDMO's growth ahead. The losses in the API and trade generics segment are tapering led by rationalising loss-making products and units, respectively.
Innova Cptab	<ul style="list-style-type: none"> Incremental contribution from the Jammu facility aided CDMO sales. API pricing continues to be weak, with prices of certain anti-infective APIs getting corrected by nearly 20%. The company works on a pass-through model and hence benefit of low API prices has to be passed on to customers, resulting in a hit to overall revenue growth while margins remain steady. Through Jammu plant, it has adequate capacity for manufacturing cephalosporin oral solid products while capacity constraint for oral liquids persists. ICL, which covers the entire manufacturing footprint of the company, has grown 26% YoY.

Source: Company data, I-Sec research

Exhibit 5: US Commentary: Q1FY26

Company	US Business Commentary
Sun Pharma	<ul style="list-style-type: none"> The company has, so far, not been contacted by the US government for any product in the portfolio for enquiry under section 232 of US tariffs. It does not plan to shift manufacturing to US, apart from what it is already manufacturing there. Management believes that the current 25% tariff on India may not include pharmaceuticals. Post section 232 investigation report, US government may decide on tariff on pharmaceuticals. Sequential revenue for gRevlimid were moderately higher. It launched 4 new products in US in Q1FY26. It shall launch Unloxcyt in H2FY26. The company is awaiting long-term data from Checkpoint, before launching Unloxcyt in US. Unloxcyt would have some prescriber overlap with Odomzo. The company is actively engaging with USFDA to find a resolution for observations at its Halol manufacturing plant.
Aurobindo	<ul style="list-style-type: none"> Decline in US revenue was due to lower sales of gRevlimid, inventory destocking due to tariff impact (~15-30 days impact). Management does not expect any material uptick in gRevlimid sales for next two quarters, however, post patent expiry (Feb'26 onwards), the company expects a significant increase in volumes. It launched 15 products in US in Q1FY26. Acquisition of Lannett will require clearance from US FTC, timeline of completion of 8-12 months can be expedited if it gets an early clearance from FTC.
Dr. Reddy's	<ul style="list-style-type: none"> US sales declined 13.8% YoY mainly due to price erosion and procurement timing by customers for Revlimid. Pricing pressure in lenalidomide is expected to intensify in the US market ahead. During the quarter, it launched five new products and filed one ANDA in the US. Base biz in US grew in the quarter and management aspires a flat to single digit growth in FY26. It may launch 20 products in US in FY26. Liraglutide will be launched in US in next couple of quarters. Dr Reddy's is likely to be the first to market gSaxenda.
Lupin	<ul style="list-style-type: none"> US revenue grew 15.1% QoQ boosted by the launch of Tolvaptan. Management expects Tolvaptan to be a formidable growth driver for the next two quarters. The company is planning to launch 20 complex products, including inhalers, injectables and ophthalmic products. The company may site-transfer a few high-value products to manufacturing site in US, if tariffs are imposed. 10-15% tariff in US is likely to be manageable for the company, beyond which it may impact the operations of the company. Most favoured nation (MFN) pricing impact shall be mostly on large value categories, where government and private spend is high. The company's status on supplies of Mirabegron shall be subject to the outcome of the litigation scheduled in Feb'26. It has launched glucagon in US on 5 Aug'25 and liraglutide will likely be launched in Oct'25. Goal date for gSaxenda approval in US is in next year, launch may happen in FY27. It may launch gRisperdal consta in Sep'25 while Dalbavancin will likely be launched in FY26. The company is in the process of responding to the CRL for gDulera. Management targets to launch this product in H2FY27 or FY28. Near-term competition risk in Albuterol and gSpiriva lingers.
Cipla	<ul style="list-style-type: none"> Cipla launched gAbraxane (2-3 companies competing) and Nilotinib in Q1FY26 which could support growth in the near term. Launch of gAdvair, gSymbicort and better market share for Lanreotide may aid growth in FY27. Sales of Lanreotide (two-player market) were flat YoY; Cipla's peak market share in this product stood at 35% (currently at 21%) and it may look to gain its lost market share in quarters ahead. Cipla has entered into a strategic agreement to launch filgrastim in the US in Q2FY26. USFDA has completed the inspection at the US plant for Advair approval. Management aims to launch this product in H2FY26 in the US. Management is committed to launch 2-3 peptide products in FY26. Inspection of Indore plant may happen before Feb'26. For the next couple of years, the company may look to in-license biosimilars. Cipla has also committed USD 100mn to a JV for the development of biosimilars. In the long term, it intends to launch its own biosimilars assets; however, those products are likely to commercialise from FY29-30.
Zydus Lifesciences	<ul style="list-style-type: none"> Sales for gRevlimid and Mirabegron were flat QoQ. Zydus has supplied majority of its fixed volumes in gRevlimid in Q1FY26 and the product may not be a material sales contributor in quarters ahead. In Q1FY26, it launched 3 new products in US. Zydus would scale up presence in specialty segment by enhancing launches of 505 b(2) and pediatric products. It plans to launch over 30 products in FY26, clearance of injectable site will likely further boost new launches. Sales of Asacol HD have declined in the quarter and witnessed decent growth in base biz. Ibrance (Palbociclib) and 505 b(2) product launches will likely boost growth in FY27. Zydus plans to acquire Agenus Inc.'s US based biologics manufacturing facilities with USD 75mn upfront payment and further USD 50mn in contingent payments.
Torrent	<ul style="list-style-type: none"> US sales growth bounced back in Q1, growing 16.1% YoY. Management aims to launch 10 products in FY26 (5 launched in Q1FY26), pipeline for FY27 remains strong. US business post R&D is still not profitable for the company. The company has launched gEntresto in US, 10 companies have launched this product.

Company	US Business Commentary
Glenmark	<ul style="list-style-type: none"> US sales declined by 2.8% YoY impacted by price erosion and lack of material launches. It launched three products in Q1. It plans to file one ANDA in Q2FY26 and 5-6 ANDAs in FY26 with 10 product launches expected in FY26 (including partnered products). Approval of its generic respiratory ANDAs is anticipated starting H2FY26. It also plans to file ANDAs for two additional strengths of gFlovent. It has 52 applications pending approval with USFDA of which 24 are Para IV. It plans to launch three injectable products through partnerships in Q2FY26. Glenmark has completed the remediation at Monroe site and is awaiting a reinspection by the USFDA. It continues to take exhibit batches at this site.
Natco	<ul style="list-style-type: none"> Exports (including profit share and subsidiaries) declined 6.9% YoY (+7% QoQ) to INR 11.3bn due to pricing pressure in US. Sales of gRevlimid was flat QoQ and management expects it to decline in H2FY26. Phase-2 trials for NCE product NRC 2694 are ongoing and 13-14 patients have been enrolled in US till now. It needs 60-70 patients to arrive at an outcome on the indication. The company plans to pass on some of the impact of the tariff to its customers, if implemented. Natco is investing in clinical trials for cancer patients (generic products and NRC 2694), peptides and oligo. Pomalidomide is approved by USFDA and settled with the innovator.
Ajanta	<ul style="list-style-type: none"> US business grew 36.0% YoY on the back of five new launches in H2FY25 and one launch in Q1FY26. It plans to launch 2-3 more products in next couple of quarters. The company plans to file 10 ANDAs in US in FY26.
Alkem	<ul style="list-style-type: none"> US revenue grew 8.8% YoY driven by base business, new launches and CDMO revenue. Price erosion in base portfolio was 3-4% YoY. In Q1FY26, it received 5 ANDA approvals and launched 3 ANDAs. Launched gEntresto in US at the time of market formation in Jul'25. Sales from the product should boost growth in Q2FY26 Alkem also filed its first biologics license application (BLA). The company has incurred capex of INR 5.5bn towards setting up a manufacturing plant in US (operational by Q3FY26) to venture into CDMO of biosimilars. Client onboarding has begun for the US plant and it has an order book (OB) that can generate revenue of INR 1bn in FY26E with peak potential of INR 4.5-5bn (1x asset turnover) in the next 2-3 years from this plant.
Gland Pharma	<ul style="list-style-type: none"> US revenue fell 2.4% YoY mainly due to 5% dip in Gland's portfolio on account of lower sales of enoxaparin (INR 700mn in Q1 vs. INR 1.4bn last year) US growth excluding sales of enoxaparin was 11% YoY. It launched nine new molecules in Q1FY26 and one RTU infusion bag, additional 10 RTU-backed products are under development. It has launched six complex injectables and three more are in line for approval. It continues to be the key focus area.

Source: Company data, I-Sec research

Exhibit 6: Tariff commentary

Company	Guidance
Sun Pharma	<ul style="list-style-type: none"> The company has, so far, not been contacted by the US government for any product in the portfolio for enquiry under section 232 of US tariffs. It does not plan to shift manufacturing to US, apart from what it is already manufacturing there. Management believes that the current 25% tariff on India may not include pharmaceuticals. Post section 232 investigation report, US government may decide on tariff on pharmaceuticals.
Aurobindo	<ul style="list-style-type: none"> US revenue growth was impacted by lower sales of gRevlimid and inventory destocking due to uncertainties over tariff (~15-30 days impact).
Lupin	<ul style="list-style-type: none"> The company may site-transfer a few high-value products to manufacturing site in US, if tariffs are imposed. 10-15% tariff in US is likely to be manageable for the company, beyond which it may impact the operations of the company. Most favoured nation (MFN) pricing impact shall be mostly on large value categories, where government and private spend is high.
Natco	<ul style="list-style-type: none"> The company plans to pass on some of the impact of the tariff to its customers, if implemented.
Alembic	<ul style="list-style-type: none"> Tariff will have larger impact on high volume and thin margin products. Complex injectables will have lower impact Management expects pharma products to be exempted from 25% tariff imposed on India. Management is not keen on increasing manufacturing presence in US to negate the impact of tariffs. It will discontinue supplies for loss-making products.
Cohance	<ul style="list-style-type: none"> The company may pass on any cost escalation due to imposition of tariff to customers. Customers are willing to bear the impact of tariff, if implemented.
Divi's	<ul style="list-style-type: none"> US government has not provided a clear methodology for tariff currently and it is not clear if intermediate and APIs fall under the ambit of tariff. Divi's has long term supply agreements which will protect it from such events Clients are yet to make any changes to their sourcing strategies.

Source: Company data, I-Sec research

Exhibit 7: Outlook

Company	Guidance
Sun Pharma	<ul style="list-style-type: none"> Revenue growth likely to be in high single digit in FY26. The company may look for opportunities to strengthen the portfolio. It may look to expand in dermatology, ophthalmology and oncology. Sun may launch lluyma for PSA indication in next 10-12 months in US. The company shall also amortise acquisition cost of Leqselvi. Besides, it would also incur a charge of USD 100mn towards marketing of Leqselvi and Unloxcyt. It aims to launch its anti-obesity and Type-2 diabetes GLP1 drug, utreglutide (GL0034), in next 4-5 years. The company has maintained R&D spending guidance of 6-8% of sales for FY26. ETR for FY26 likely to be at 25%; cash tax rate may be lower than this rate.
Aurobindo	<ul style="list-style-type: none"> The company has maintained EBITDA margin guidance of 20-21% for FY26. Revenue contribution from China plant will start from Q2FY26 and operations are likely to achieve EBITDA breakeven by Q3FY26. Supplies to three biosimilars for Europe is likely in H2FY26. In Biologic CMO, the company will further add two more mammalian lines (capex of INR 3.5-4bn) by FY28. Gross margin in biosimilars' business is likely to be ~50%. Management believes its EBITDA margin in biosimilars will be better than company-level margin. The company maintains revenue guidance of over Euro 1bn from Europe in FY26. Management is confident of scaling up manufacturing to 7000-9000 tons at Pen-G plant in the near term, expects PLI incentive of INR 1.5bn in FY26 and positive EBITDA from Q3FY26.
Dr. Reddy's	<ul style="list-style-type: none"> DRL is set to launch Semaglutide (gOzempic) in Canada in Jan'26. It has a capacity of 12mn pen with contract manufacturer and is also incurring capex of INR 30bn towards setting capacities for GLP-1 and biosimilar products. Phase 3 trial readout for bAbatacept is expected by Nov'25 and market formation for IV route is expected in Jan'27. It continues to aspire double digits growth in India. Gross margin may remain at current levels of 57-58% in FY26. Launch of Semaglutide may improve gross margin in FY27. Cost synergies of 500-600bps are possible on current cost base. R&D spending will be restricted to 7-7.5% of sales in FY26. ETR will be at 25% for FY26. It plans to incur capex of INR 25-27bn in FY26 towards peptides and biosimilars. PLI incentives are expected to decline substantially in FY26 as the company has booked higher incentives in earlier years.
Divi's	<ul style="list-style-type: none"> Company is targeting equal contribution from generics and CS segments in the near term. It will incur capex of INR 20bn in FY26. Supplies of generics to regulated markets from Kakinada are likely to begin in FY27 and will be instrumental in reviving growth in the generics segment. Divi's is also investing INR 7bn in each of its two new CS projects announced for APIs and advanced intermediate manufacturing, which may drive growth from FY28/29 for the company.


Company	Guidance
	<ul style="list-style-type: none"> It has forward-integrated into the manufacturing of solid and liquid phases of peptide synthesis for GLP-1 products. It is working with innovators on multiple GLP-1 products. It is working with several innovators on gadolinium-based compounds which are currently in various phases and plans to launch in 12-24 months. The company is trying to diversify its business model by adding more generic molecules to its basket, foray in peptide, contrast media, flow chemistry, bio-catalyst and green chemistry are a few steps in this direction.
Cipla	<ul style="list-style-type: none"> Management has maintained its margin guidance of 23.5-24.5% for FY26. Other expense run-rate is likely to be maintained for next couple of quarters. Remediation cost is likely to come down post the inspection at Indore facility. Management aspires to grow India business in line with market growth rate in FY26. Trade generics segment is expected to grow at 8-10% in FY26. US sales may touch USD 1bn by FY27. Impact of lower revenue of gRevlimid will be mitigated through new launches. It aims to be in the first wave of launch in for most of the GLP-1 drugs. Focus in South Africa is towards margin improvement. Focussing on boosting growth and maintaining the current margin profile in EM and EU.
Lupin	<ul style="list-style-type: none"> Management has guided for double-digit growth in US and expansion of overall business in FY26. EBITDA margin is likely to be between 24-25% for FY26. In FY27, it aspires to achieve high single-digit revenue growth and is confident of enhancing its margins in FY27. R&D spending would be at 8.5% of sales in FY26. ETR shall be ~19% in FY26. Diagnostic business in India will likely break-even next year. Semaglutide will be launched through a partner in Canada. Partner is still in the process of securing approval from the Canadian regulatory body for semaglutide.
Zydus Lifesciences	<ul style="list-style-type: none"> The company is on track to achieve over 26% EBITDA margin in FY26. Capex of INR 12bn (including INR 3bn for dialyzer facility) planned for FY26. Management has maintained single-digit growth guidance in US for FY26 led by 505 b(2) and other new launches. Management expects 15-25% growth in Europe and emerging markets in FY26. CUTX 101 approval expected in FY26. Saroglitazar data read-out is likely to happen in next couple of months, if favourable then NDA will be filed with the USFDA. Zydus has partnered for desidustat in China, where Zydus is in process of launching the product and approval is anticipated in FY26. The company shall have a markup on supplies of this product plus royalty income on sales of desidustat in China.
Torrent Pharma	<ul style="list-style-type: none"> EBITDA margins are unlikely to go below ~33% in FY26. The company has filed an application with CCI for acquisition of JB Chemicals. The acquisition of the initial 49.2% stake at INR 119.2bn in JB Chemicals is likely to be completed in the next five months and would be funded through debt. 25% ETR in India and 25-26% on consolidated business. Management expects 10-11% growth in Brazil in constant currency terms in FY26. In Brazil, generic launch in Wegovy in Brazil is expected to happen at a later date and management does not expect off-label use of Ozempic for weight loss. Growth across Germany is expected to be tepid in coming quarters, as regulatory issue at the supplier's plant will likely take time to resolve.
Biocon	<ul style="list-style-type: none"> Management is targeting double-digit growth in generics segment in FY26. Syngene remains on track to deliver double-digit growth aided by new launches. Interest cost is expected to start declining Q2FY26 onwards. It raised INR 45bn in equity capital through a QIP to retire OCD of Goldman Sachs (USD 200mn) and NCDs of Kotak and Edelweiss, post which Biocon's stake in Biologics will increase to 78%. Bayview facility in the US is on track for commissioning later this year. Margins of biologics are expected to improve led by the recent launches and new launches lined ahead. Injectable manufacturing facility primarily focused on GLP-1s in Bangalore has been commissioned with commercialisation expected in FY27. In India, Liraglutide (gVictoza) will be launched through partner in Q2FY26. Biocon will be vertically integrated in this product. Liraglutide has been filed in the US; approval and launch likely in FY26 Semaglutide will be filed in Q2FY26 across many emerging markets and Canada. Management anticipates to launch this product across markets in CY26-27.
Alkem	<ul style="list-style-type: none"> Management aims for India business to outpace IPM growth rate (pegged at 7-8%) by 100-150bps in FY26. Management maintains mid-single-digit growth guidance in US in FY26. Gross margins are expected to be ~64% in FY26. EBITDA margins are expected to be between 19.5-20% in FY26. Spending will be higher in H2FY26 towards new initiative like biotech plant and med tech biz, exerting pressure on margins. Targeting 100bps margin improvement every year till it achieves company level margins of ~25% R&D spending would be ~4.5-5% in FY26. The company plans to launch new products in RoW markets towards which it is incurring higher R&D. It shall incur capex of INR 7.5bn in FY26 and the tax rate is expected to be between 13-15%.

Company	Guidance
	<ul style="list-style-type: none"> New biotech plant in US is expected to commercialise in H2FY26. The plant could incur EBITDA loss of INR 400-500mn per quarter in FY26 and FY27 and breakeven is targeted in FY28. The med-tech business is expected to generate sales of INR 200mn in FY26 with INR 250-300mn operating cost per quarter. Branded biz is of highest priority for management, followed by CDMO and biotech biz. Next two quarters are expected to be strong for India business. The biologics CDMO plant in US is expected to commence operations in H2FY26.
Glenmark	<ul style="list-style-type: none"> It expects gross margin to remain at ~68% supported by branded products. Management aims to scale up EBITDA margin to ~23% from Q3FY26. Net working capital days between 110-115 days are sustainable on long-term basis. R&D spend is likely to be ~7.5% of sales in FY26. The company expects the in-licensed portfolio to account for USD 350-400mn sales (five existing assets) over the next 5-7 years, from current levels of USD 100mn (Ryaltris). India business is expected to grow at CAGR of 10-15% over the next 3-5 years. Management expects India biz growth to be in line with secondary market growth from Q3FY26. Glenmark's partner in Mainland China, Grand Pharmaceutical (China) Co. Ltd., expects to receive the approval for Ryaltris in FY26. Glenmark had filed QINHAYO in ~15 markets in FY25 with the first market launch expected in FY26 Management anticipates double-digit growth in FY26 on a constant currency basis in EMs. Ryaltris and Qinhayo expected to contribute to majority of growth in EMs. ISB 2001 out-licensing deal with Abbvie will be closed by Sept'25. Glenmark will continue to incur dose expansion-related expenses till the deal is closed It is likely to incur R&D spend of ~USD 70mn p.a. in each of the next 3 years in IGL. Post Abbvie deal, the company expects to turn cash positive on consolidated level. The company is awaiting re-inspection of Monroe plant and expects to start commercial manufacturing in FY26.
Natco	<ul style="list-style-type: none"> South Africa (Adcock Ingram) will be 15-20% of the base earnings in FY27 post Revlimid. Expect the transaction to be completed in next 2-3 months. Natco would consolidate 35.75% of Adcock's PBT in its financials, post completion of the transaction. The company plans to further acquire an asset that would strengthen its base business; hence, it has taken enabling resolution from shareholders for increasing the authorised share capital. It is exploring an inorganic opportunity that can strengthen its base business in a new or existing market. R&D expenses shall start declining from H2FY26. R&D cost to be ~4bn in FY26. In agrochemicals segment, company is on track to achieve INR 1.5-1.6bn sales in FY26. EBITDA breakeven expected in FY26. It has 10 niche molecules in development pipeline, including NCEs, oligonucleotides and other complex products and is looking to add five more molecules to its development pipeline in the near term.
Ajanta Pharma	<ul style="list-style-type: none"> Branded generic business in India is expected to grow at 1.25x market growth rate ahead. Trade generics business growth likely at 10% in FY26. Quarterly revenue run-rate in US should sustain in current year. In Asia, 250 MRs to be added in FY26, taking the total count to 2,250 at end of FY26. Business to grow in mid teens going forward. Management expects Africa business to grow in mid to high single digit in FY26. EBITDA margin for FY26 would be between 26-28%. Margins are expected to expand in FY27. ETR likely to be ~23%. Capex for FY26 would stand at INR 3bn, towards corporate office and an oral liquid manufacturing plant for RoW markets. Working capital cycle is at efficient levels and scaling it down from current levels may not be possible. M&A focus shall be towards acquiring branded generic assets in India, Asia and Africa.
Alembic Pharma	<ul style="list-style-type: none"> In FY26, US business is likely to grow at 10-15% backed by 15 launches. Management is confident of resolving execution challenges in specialty segment in a couple of months and reviving double-digit growth in India. Growth from RoW market is likely to be 10-15% in FY26. R&D cost is likely to be INR 6-6.5bn in FY26, to be spent towards development of peptides and other complex products. ETR likely to be in the range of 17-18% in FY26. It is likely to incur capex of INR 4bn mainly towards maintenance with some part for expansion. API growth is likely to be muted for couple of quarters ahead.
JB Chemicals	<ul style="list-style-type: none"> Domestic business growth to be in the range of 12-14%. Branded generic business to ramp up in H2FY26, expect high single-digit growth by Q3FY26. CDMO growth of 12-14% is expected in FY26 and average quarterly run-rate of INR 1.2bn in Q2FY26, INR 1.3bn in H2FY26 and INR 1.4-1.5mn in FY27. Demand pickup in Russia expected from H2FY26 while South Africa is expected to improve with grants and sanctions coming in. There was slight pricing pressure in US; however, witnessing good order visibility for the next 6 months. Phase-1 approval for 8-10 molecules across 14-16 markets in RoW expected from Sep'25 and phase 2 approvals expected in H2FY27. The management has maintained gross margin guidance of 67% and EBITDA margin guidance of 27-29% for FY26.


Company	Guidance
Piramal	<ul style="list-style-type: none"> Management expects a strong recovery in H2FY26. The company expects double-digit growth in CHG segment in FY26, driven by RoW markets with H2 to be much stronger. Management maintained guidance of mid-teen revenue growth (ex-one product), mid-teen EBITDA margin for FY26 and YoY growth in net profit in FY26. It continues to aspire to achieve USD 2bn in revenue with 25%+ EBITDA margin by FY30. In medium term, gross margin may be between 64-65%, it is expected to improve as quantum of innovative products increases. ETR is expected to be lower led by improvement in performance of overseas subsidiary (benefits in US, R&D tax credit at Canadian facility). Capex to be in the range of USD 100-125mn mainly for expansion at Lexington facility, CHG business and maintenance. Overall debt to equity is currently at 2.6x and is expected to increase slightly in FY26, aim is to bring it down to 1x by FY30.
GSK	<ul style="list-style-type: none"> Management is targeting double-digit growth for FY26. Current level of EBITDA margin of ~31% is likely to sustain in FY26, as marketing spend on new launches may not be very high. Q2 and Q3 are likely to be strong for the company and it would also benefit from price hikes taken by the company. GSK plans to launch patented oncology brands Zejula and Jemperli in Q2FY26. Shingrix is likely to touch monthly sales of 100,000 doses per month and exit FY26 with annualised revenue of INR 1bn. Trials for RSV (respiratory syncytial virus) vaccine are ongoing in India and launch is expected by end-CY26. It is also conducting trials for Bepirovirsen (first treatment for Hep-B) and its global launch is expected in the next 18 months. The supply issues with regard to Calpol were resolved in Jul'25 and growth in the brand is expected to recover.
Akums	<ul style="list-style-type: none"> Management has revised its guidance to mid-single-digit growth for the CDMO segment with margin between 14-15%. CDMO volume growth is expected to pick up going ahead; 2-3% growth would be aided by better volumes and 2-3% from product mix. The company does not intend to hike prices. Margins in domestic branded segment are expected to remain stable at 18% for FY26. High-teen growth is expected in international branded segment in FY26. API losses may shrink by ~INR 200mn in FY26. Supplies for 5-year European contract shall begin in Apr'27. Cash balance of INR 15.2bn may be deployed for acquisition of new dosage form capabilities and access to other markets. Baddi facility shall commence commercial supplies from Q2 while oncology block to begin from H2FY26 and Serodol block in Q1FY27. Akums has started building pipeline for the European market; currently, it has 15 products at different phases of production. Focus is on products with limited competition. It has received Brazil ANVISA approval for injectable plant 3 and GMP Russia for hormonal plant 4. Domestic branded-formulations' growth would be in line with IPM growth ahead. Targeting USD 100mn (currently ~USD 15mn) in exports in the next 5 years (CDMO and international branded). Capex for the Jammu facility shall begin from end-FY26. Management expects high-teen growth in FY26.
Innova Captab	<ul style="list-style-type: none"> Management aims to achieve quarterly run-rate of INR 1bn at the Jammu facility in FY26 (maintains full year guidance of INR 4bn). Rapid pick-up in product shipments from Jammu plant in next couple of quarters is likely to help the company offset the impact of API price softening in the near term. Product transfer from Baddi plant to Jammu will complete by end of FY26. Customers are auditing the Jammu plant and the initial feedback is positive. Supplies to more customers are expected to begin in H2FY26. Jammu plant is expected to achieve EBITDA breakeven in Q2FY26 and will start generating positive cash FY27 onwards. Momentum in branded generics business is expected to be maintained going forward.
Cohance Lifesciences	<ul style="list-style-type: none"> Management has maintained guidance of achieving USD 1bn revenue by 2030. Maintained double digit revenue growth in FY26. EBITDA margin guidance for FY26 maintained – it is likely to be ~30-32% in the near term and shall be scaled to ~35% in the medium term. The company's partner has received USFDA approval for a product, which may be commercialised soon. It will be incurring capex of USD 10mn for this bioconjugation cGMP suite. Improvement in product mix coupled with incremental contribution from niche technical capabilities like ADCs, peptides and oligonucleotide fragments will likely drive growth. Share of niche technologies is set to rise for current levels of 20% to mid-20s in FY26. In FY26, the company would work towards integration and scale of the acquired NJ Bio (EBITDA margin at 10%) while inventory destocking may also exert some pressure on margins. The company is also setting up a dedicated site for specialty chemicals at its Vizag (Nacharam) plant, which remains on track to initiate operations by end-CY25. Management anticipates healthy growth to sustain in FY26 and is also looking to collaborate with a Japanese client for addition of molecules in agro and specialty chemicals segments.
Gland Pharma	<ul style="list-style-type: none"> The company is on track to deliver mid-teen growth in FY26 while EBITDA is likely to be ~24-25% in FY26. Cenexi may be impacted slightly in Q2FY26 due to planned plant shutdown; however, management has guided for high single digit EBITDA margin for FY26 and low teen for FY27.

Company	Guidance
	<ul style="list-style-type: none"> • In Cenexi, a new pre-filled syringe line is on schedule to be operational in early 2026, which will substantially increase capacity. • In FY27, cartridge capacity for GLP-1 products is expected to achieve 50% utilisation. • Gland's base business growth (~3% YoY in Q1FY26) is expected to improve ahead led by new launches and improvement in existing business. • The company is also incurring growth capex of USD 100mn in Cenexi to increase capacity for value-accretive business, which should enable the company to turn profitable in the next couple of years. • Capacity addition of GLP-1/Pen/cartridge from 40mn to 140mn units (by Mar'26) will be sufficient to boost growth post FY28. • In FY27, GLP-1 products are likely to utilise 50% of its existing capacity of 40mn units. • gWegovy is likely to become a big opportunity for the company in FY30. • Revenue from collaboration with Dr Reddy is likely to start from Q2FY26.


Source: Company data, I-Sec research

Exhibit 8: Domestic business grew driven by better volumes and price hikes



Source: Company data, I-Sec research

Exhibit 9: US – dip led by pricing pressure in gRevlimid



Source: Company data, I-Sec research

Exhibit 10: Revenue of our coverage universe grew 8.0% YoY



Source: Company data, I-Sec research

Exhibit 11: Higher RM cost and lower sales of gRevlimid led to flattish margins


Source: Company data, I-Sec research

Exhibit 12: Sequential improvement was led by lower R&D cost



Source: Company data, I-Sec research

Exhibit 13: Adj. profit for our pharma coverage universe was up 5.9% YoY



Source: Company data, I-Sec research

Price charts


Sun Pharma




Dr Reddy's




Aurobindo




Lupin




Cipla




Zydus Lifesciences




Biocon




Glenmark




Torrent



Alkem




Ajanta




Alembic




Gland Pharma




JB Chemicals




Natco




Abbott India




Pfizer India




GSK Pharma




Divi's




Piramal Pharma




Akums



Innova Captab



Cohance



Source: Bloomberg

"In case of industry/sector reports or a report containing multiple stocks, the rating/recommendation for a particular stock may be based on the last released stock specific report for that company."

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com and Kadambari_balachandran@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

*New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)
BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return*

ANALYST CERTIFICATION

I/We, Abdulkader Puranwala, MBA; Nisha Shetty, MBA; Darshil Jain, MBA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is SEBI registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report.

Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

ICICI Securities Limited has not used any Artificial Intelligence tools for preparation of this Research Report.

SEBI Guidelines for Research Analyst (RA) requires all RAs to disclose terms and conditions pertaining to Research Services to all clients. Please go through the "Mandatory terms and conditions" and "Most Important Terms and Conditions. ([Link](#))

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, **E-mail Address** : complianceofficer@icicisecurities.com

For any queries or grievances: [Mr. Bhavesh Soni](#) Email address: headservicequality@icicidirect.com Contact Number: 18601231122
